A Therapeutic Antiviral Antibody Inhibits the Anterograde Directed Neuron-to-Cell Spread of Herpes Simplex Virus and Protects against Ocular Disease
Open Access
- 31 October 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 8, 2115
Abstract
Herpes simplex virus (HSV) is a leading cause of blindness and viral encephalitis in the developed world. Upon reactivation from sensory neurons, HSV returns via axonal transport to peripheral tissues where it causes e.g. severe, potentially blinding ocular diseases. In the present study we investigated whether the HSV-1/2 glycoprotein B specific antibody mAb 2c or its humanized counterpart mAb hu2c can protect from ocular disease in a mouse model of HSV-1 induced acute retinal necrosis (ARN). In this model the viral spread from the initially infected to the contralateral eye resembles the routes taken in humans upon HSV reactivation. Systemic antibody treatment prior or early after infection effectively protected the mice from the development of ARN. These observations suggest that the antibody potently neutralized the infection and inhibited the viral transmission, since there was almost no virus detectable in the contralateral eyes and trigeminal ganglia of antibody treated mice. Besides of neutralizing free virus or limiting the infection via activating the complement or cellular effector functions, blocking of the anterograde directed neuron-to-cell spread of HSV represents a viable mode of action how mAb 2c protected the mice from ARN. We proved this hypothesis using a microfluidic chamber system. Neurons and epithelial cells were cultured in two separate compartments where the neurons sent axons via connecting microgrooves to the epithelial cells. Neurons were infected with a reporter HSV-1 strain expressing mCherry, and the co-culture was treated with neutralizing antibodies. In contrast to commercial polyclonal human HSV-neutralizing immunoglobulins, mAb 2c effectively blocked the anterograde directed neuron-to-cell transmission of the virus. Our data suggest that the humanized HSV-1/2-gB antibody protects mice from ocular disease by blocking the neuronal spread of HSV. Therefore, mAb hu2c may become a potent novel therapeutic option for severe ocular HSV infections.Keywords
This publication has 55 references indexed in Scilit:
- Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibodyProceedings of the National Academy of Sciences, 2013
- Alphaherpesvirus axon-to-cell spread involves limited virion transmissionProceedings of the National Academy of Sciences, 2012
- Herpesvirus infections of the central nervous system in immunocompromised patientsTherapeutic Advances in Neurological Disorders, 2012
- Visualization of an Alphaherpesvirus Membrane Protein That Is Essential for Anterograde Axonal Spread of Infection in NeuronsmBio, 2012
- Corneal Penetration of Topical and Subconjunctival BevacizumabInvestigative Ophthalmology & Visual Science, 2011
- Impact of Valency of a Glycoprotein B-Specific Monoclonal Antibody on Neutralization of Herpes Simplex VirusJournal of Virology, 2011
- Anterograde Spread of Herpes Simplex Virus Type 1 Requires Glycoprotein E and Glycoprotein I but Not Us9Journal of Virology, 2009
- Virion-Incorporated Glycoprotein B Mediates Transneuronal Spread of Pseudorabies VirusJournal of Virology, 2009
- Genital herpes and its managementBMJ, 2007
- Herpes Simplex Virus Capsids Are Transported in Neuronal Axons without an Envelope Containing the Viral GlycoproteinsJournal of Virology, 2006